… Hypothetically the pathogenesis of APS pregnancy morbidity depends on the thrombogenic
effect of antiphospholipid antibodies (aPL) that may cause a slow, progressive thrombosis …

… antiphospholipid antibodies (anticardiolipin antibodies or aβ2GPI) in 9.6% (56/582) of fetal
deaths at >20 weeks’ gestation, and therefore threefold to fivefold increased odds of stillbirth.…

… test positive for aPL using international criteria for antiphospholipid antibody (aPL) assays. …
APS include specified levels of at least one antiphospholipid antibody (aPL) and at least one …

… High-risk antiphospholipid antibody (aPL) profile is associated with greater risk for
thrombotic and obstetric APS. Risk modification includes screening for and management of …

… test results for anticardiolipin antibodies or anti-b2GPI) [23]. It has been shown that confirmation
of aPL positivity on two occasions at least 12 weeks apart was usually associated with …

… Obstetric APS management should be tailored based on an individual patient’s antiphospholipid
antibody profile, and obstetric and thrombotic history. Pharmacological agents beyond …

… antiphospholipid antibodies (aPLs).1 The major goal of the management of APS is the
prevention of first or recurrent thrombotic or obstetric complications. Oral anticoagulation with …

… While the definitive role of statins for primary thrombosis prevention among aPL-positive
patients remains unclear, the 16th International Congress on Antiphospholipid Antibodies …

… Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with
recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). …

… PE (8.4), chronic hypertension (5.1) and antiphospholipid antibodies (2.8). The results of the
… obesity, diabetes, prior PE and antiphospholipid antibodies, and it additionally revealed that …